SCHEDULE: ADAR1 Capital Management Reports 5.4% Stake in BioAge Labs

ADAR1 Capital Management and Daniel Schneeberger report beneficial ownership of 5.4% of BioAge Labs' common stock as of June 30, 2025.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Schedule 13G with the SEC on August 14, 2025, reporting their ownership in BioAge Labs, Inc.
• As of June 30, 2025, ADAR1 Capital Management and Daniel Schneeberger beneficially own 1,937,123 shares of BioAge Labs' common stock, representing 5.4% of the outstanding shares.
• The reported shares are held by ADAR1 Partners, LP (1,662,162 shares) and Spearhead Insurance Solutions IDF, LLC (274,961 shares).
• Daniel Schneeberger, as the manager of ADAR1 Capital Management, LLC, may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
• The filing is based on 35,850,037 shares of BioAge Labs, Inc. common stock outstanding as of June 30, 2025, as reported in the Issuer's 10-Q, filed with the SEC on August 6, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing is a standard disclosure of ownership.

Positives

• ADAR1 Capital Management's investment reflects confidence in BioAge Labs' prospects.

Future Outlook

NA

Industry Context

This filing indicates institutional investor interest in the biotechnology sector, specifically in companies like BioAge Labs.

Stakeholder Impact

• Shareholders: Increased institutional ownership may influence stock price and stability.
• Company: Management may need to engage with ADAR1 Capital Management as a significant shareholder.

Key Dates

Recommendation

The filing indicates a significant ownership stake by an investment firm, which could provide stability but doesn't necessarily warrant a buy or sell recommendation without further analysis of the company's fundamentals.

Keywords

BioAge Labs, ADAR1 Capital Management, Daniel Schneeberger, Schedule 13G, Beneficial Ownership, Investment, SEC Filing